What is Kyle Jenne’s remaining Ionis Pharmaceuticals (IONS) share ownership after these transactions?

After the reported option exercises and sales, Kyle Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock. This figure reflects his post-transaction position as shown in the Form 4, indicating he retained a meaningful equity stake in the company.

Ionis EVP exercises options, sells 37,277 shares

Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade. He exercised options for 37,277 shares of Common Stock at exercise prices of $34.69 and $46.10 per share, then sold 37,277 shares in open-market transactions at weighted average prices of $75.502 and $76.30 per share.

The sales were made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 37,277 shares ($1.16M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Jenne Kyle

Role EVP, Chf GL Pdt Str Ofcr

Sold 37,277 shs ($2.83M)

Approx. gross sale proceeds $2.83M

Approx. exercise cost $1.67M

Approx. pre-tax spread $1.16M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	4,675	$0.00	$0.00
Exercise	Non-Qualified Stock Option (right to buy)	32,602	$0.00	$0.00
Exercise	Common Stock	32,602	$46.10	$1.50M
Sale	Common Stock	21,191	$75.502	$1.60M
Sale	Common Stock	16,086	$76.30	$1.23M
Exercise	Common Stock	4,675	$34.69	$162K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 46,626 contracts (Direct); Common Stock — 16,389 shares (Direct)

Footnotes (3)

F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

FAQ

What did Ionis Pharmaceuticals (IONS) EVP Kyle Jenne report in this Form 4?

EVP Kyle Jenne reported exercising stock options and selling shares of Ionis Pharmaceuticals Common Stock. He exercised 37,277 options and sold 37,277 shares in open-market trades, all on March 10, 2026, under a pre-established Rule 10b5-1 trading plan.

How many Ionis Pharmaceuticals (IONS) shares did Kyle Jenne sell and at what prices?

Kyle Jenne sold 37,277 shares of Ionis Pharmaceuticals Common Stock. The sales occurred in multiple transactions, with weighted average prices of $75.502 and $76.30 per share, reflecting execution across price ranges specified in the Form 4 footnotes.

How many Ionis Pharmaceuticals (IONS) options did Kyle Jenne exercise in this filing?

He exercised options covering 37,277 shares of Ionis Pharmaceuticals Common Stock. These included 4,675 options with a $34.69 exercise price and 32,602 options with a $46.10 exercise price, both originally granted as non-qualified stock options with future expiration dates.

Were Kyle Jenne’s Ionis Pharmaceuticals (IONS) stock sales pre-planned?

Yes. The Form 4 states that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Kyle Jenne on December 8, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing in evaluating the transactions.

What types of securities were involved in Kyle Jenne’s Ionis Pharmaceuticals (IONS) Form 4?

The filing involves non-qualified stock options and Common Stock of Ionis Pharmaceuticals. Jenne exercised options into Common Stock and then sold Common Stock in open-market transactions, with all ownership reported as direct rather than through an intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/11/2026 - 04:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenne Kyle

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

92010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chf GL Pdt Str Ofcr

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/10/2026		M		32,602	A	$46.1	48,991	D
Common Stock	03/10/2026		S		21,191⁽¹⁾	D	$75.502⁽²⁾	27,800	D
Common Stock	03/10/2026		S		16,086⁽¹⁾	D	$76.3⁽³⁾	11,714	D
Common Stock	03/10/2026		M		4,675	A	$34.69	16,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$34.69	03/10/2026		M			4,675	01/02/2026	01/01/2035	Common Stock	4,675	$0.0	14,025	D
Non-Qualified Stock Option (right to buy)	$46.1	03/10/2026		M			32,602	02/26/2025	02/25/2034	Common Stock	32,602	$0.0	32,601	D

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.005 to $76.00 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Kyle Jenne	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR